Gubra combines quantitative light-sheet fluorescence microscopy and atlas guided stereotactic surgery to deliver outstanding preclinical CNS endpoints
Our preclinical CRO services enable pharmaceutical and biotech companies to make fast and solid data-driven decisions moving preclinical target and drug discovery projects forward. We maintain a constant focus on providing solid data as well as completing projects on time, within budget and according to the highest scientific standards.
Our services include preclinical studies in a wide variety of rodent models of metabolic and CNS diseases, which can be adapted according to the specific scientific question in focus.
We offer automated, atlas-guided stereotactic surgical procedures in gene therapy and drug distribution studies.
Our state-of-the art light sheet imaging platform enables 3D visualization, anatomical mapping and quantification of disease marker architecture, therapeutic endpoints and drug distribution in whole organs at single cell resolution. Our high-throughput 3D imaging pipeline integrates deep learning computational analysis for fully automated atlas-guided, quantitative analysis throughout the intact brain.